ReviewMolecular neurodegeneration advances2026
Spatial transcriptomics in Alzheimer's disease: technologies, challenges and discoveries.
Review in Molecular neurodegeneration advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a complex neurodegenerative disorder that is associated with cognitive decline in the elderly. While β-amyloid (Aβ) plaques and neurofibrillary tau tangles have been used to define and stage AD onset in human brain, how these pathologies can affect various cell types nearby remains a subject of intense interest in the field. Recent developments in spatial transcriptomic technology have seen accelerated growth, and spatial transcriptomic platforms have been used independently or together with single cell transcriptomic methods to characterize cellular changes in the AD brain from mouse models and human. Here, we review current-era spatial transcriptomic technologies, analytical pipelines and their implementation in AD research. We summarize findings from spatial transcriptomics in AD, and discuss limitations and challenges associated with various spatial transcriptomic platforms. The pathological hallmarks for AD were described by Alois Alzheimer over a century ago; from the convergence of a century of AD research and technological advances in imaging and transcriptomics, a new era in AD has emerged. Although current-era spatial platforms feature limitations and challenges, evolution of spatial transcriptomics and its combined implementation with other data modalities promises significant strides in AD and related neurodegenerative disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.